EAM
DBTX

Eventide Asset Management’s Decibel Therapeutics, Inc. Common Stock DBTX Stock Holding History

Eventide Asset Management’s Portfolio DBTX Stock Details DBTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-200,000
Closed -$2.27M – 166
2021
Q1 		$2.27M Buy
+200,000
New +$3.14M 0.03% 147

Other funds holding DBTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Bessemer Group
Bessemer Group Woodbridge, New Jersey $72.7B AUM 39.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Eventide Asset Management's DBTX Position: Q2 2021 in Review

Eventide Asset Management sold out of Decibel Therapeutics, Inc. Common Stock (DBTX) in Q2 2021, closing a stake of 200,000 shares — an estimated $2.27M sold.

Eventide Asset Management first reported a position in DBTX in Q1 2021 and held it in 1 quarter. The position peaked at $2.27M in Q1 2021. 46 funds tracked by Wall St. Rank hold DBTX as of Q2 2021.

  • Eventide Asset Management reported no remaining Decibel Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Eventide Asset Management sold 200,000 Decibel Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $2.27M.
  • Eventide Asset Management first reported a position in Decibel Therapeutics, Inc. Common Stock in Q1 2021 and held it in 1 quarter.
  • Eventide Asset Management's Decibel Therapeutics, Inc. Common Stock position peaked at $2.27M in Q1 2021.
  • 46 funds tracked by Wall St. Rank held Decibel Therapeutics, Inc. Common Stock as of Q2 2021.

Based on Eventide Asset Management's 13F filing for Q2 2021, filed 16 Aug 2021.